Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Aug 1;10(8):810-818.
doi: 10.1001/jamacardio.2025.1603.

AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank

Harpreet S Bhatia  1 , Matthew Ambrosio  2 , Alexander C Razavi  3 , Pamela L Alebna  4 , Calvin Yeang  1 , Jared A Spitz  5 , Jaideep Patel  6 , Michael Y Tsai  7 , Laurence Sperling  3 , Michael D Shapiro  8 , Sotirios Tsimikas  1 , Anurag Mehta  4
Affiliations
Multicenter Study

AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank

Harpreet S Bhatia et al. JAMA Cardiol. .

Abstract

Importance: Lipoprotein(a) [Lp(a)] is independently associated with atherosclerotic cardiovascular disease (ASCVD) risk but is not included in the new American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) equations for CVD risk assessment.

Objective: To evaluate the performance of these equations in individuals with elevated Lp(a).

Design, setting, and participants: Cohort study involving 314 783 participants from the multicenter Multi-Ethnic Study of Atherosclerosis (MESA, 2000-2018; n = 6670) and the population-based UK Biobank (UKB, 2006-2022; n = 308 113) without known cardiovascular disease with available Lp(a) measurements. Analyses were conducted March 25, 2025.

Exposure: Elevated Lp(a) level of 125 nmol/L or higher.

Main outcomes and measures: Coronary heart disease (CHD), ASCVD, heart failure (HF), and total CVD. Participants were categorized as low (<5%), borderline (5% to <7.5%) intermediate (7.5% to <20%), and high (≥20%) risk of each outcome. Ten-year observed event rates were calculated, and the association between elevated Lp(a) and outcomes overall and by risk category was evaluated in age- and sex-adjusted Cox proportional hazards models. Improvement in risk prediction with the addition of elevated Lp(a) was evaluated using continuous and categorical net reclassification improvement (NRI) (using the above cut points).

Results: Among the 314 783 participants (mean [SD] age, 62.1 [10.2] years and 3523 females [53%] in MESA; mean [SD] age, 56.3 [8.1] years; 169 648 females [55%] in the UKB), observed 10-year ASCVD event rates generally fell within the bounds of predicted risk categories regardless of Lp(a) level, although participants with elevated Lp(a) had higher event rates than did those with nonelevated Lp(a) (hazard ratio [HR], 1.30; 95% CI, 1.22-1.38) with similar results for CHD, HF, and total CVD. For CHD, the strongest association was among low-risk individuals (P for interaction = .31). The addition of elevated Lp(a) values to PREVENT modestly improved ASCVD risk prediction (category-free NRI, 0.058; 95% CI, 0.043-0.065; categorical NRI, 0.006, 95% CI, 0.004-0.011) with the greatest improvement in borderline-risk; when Lp(a) was evaluated continuously, the greatest improvement in prediction was among individuals at low risk. For CHD, the greatest improvement in prediction was in low- and high-risk individuals.

Conclusions and relevance: In this analysis of 2 cohort studies, the novel PREVENT equations performed well for risk prediction overall, including among individuals with elevated Lp(a). However, Lp(a) values remain independently associated with higher risk, and Lp(a) may improve personalized risk assessment, particularly among specific subgroups.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bhatia reported receiving consulting fees from Abbott, Arrowhead, Kaneka, and Novartis outside the submitted work. Dr Shapiro reported receiving grants from Amgen, 89Bio, Esperion, Novartis, Ionis, Lilly, Merck, and New Amsterdam and personal fees from Amgen, Arrowhead, Novartis, Ionis, Merck, New Amsterdam, Novo Nordisk, and Tourmaline outside the submitted work. Dr Tsimikas reported being a coinventor and receiving royalties patents owned by the University of California, San Diego; being a founder of with equity interest in Oxitope and Kleanthi Diagnostics; receiving consulting fees from Novartis; and having a dual appointment at University of California, San Diego, and Ionis Pharmaceutical, which is an arrangement that has been reviewed and by the University of California, San Diego, in accordance with its conflict-of-interest policies. Dr Mehta reported receiving grants Novartis and Amgen paid to the Virginia Commonwealth University outside the submitted work. No other disclosures were reported.

Comment on

References

    1. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042 - DOI - PubMed
    1. Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet. 2024;404(10459):1255-1264. doi: 10.1016/S0140-6736(24)01308-4 - DOI - PubMed
    1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232. doi: 10.1016/j.jacc.2019.03.010 - DOI - PMC - PubMed
    1. Mach F, Baigent C, Catapano AL, et al. ; ESC Scientific Document Group . 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455 - DOI - PubMed
    1. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016 - DOI - PubMed